Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$108.88

2.97 (2.80%)

, NFLX

Netflix

$339.65

18.37 (5.72%)

11:01
10/12/18
10/12
11:01
10/12/18
11:01

Fly Intel: Today's top analyst calls on Wall Street

Check out today's top analyst calls from around Wall Street, compiled by The Fly. MICROSOFT UPGRADED TO OUTPERFORM AFTER PULLBACK: Macquarie analyst Sarah Hindlian upgraded Microsoft (MSFT) to Outperform from Neutral and raised her price target on the shares to $121, saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work. CITI UPGRADES NETFLIX TO BUY: Citi analyst Mark May upgraded Netflix (NFLX) to Buy from Neutral with an unchanged price target of $375. The valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy, May said. Netflix has a highly recurring subscription-based revenue business that delivers "significant value" to consumers, and its management team has a strong track record of execution, the analyst contended. Further, he believes the company's fundamentals remain strong and that is has opportunity to continue growing international subscribers. SQUARE UPGRADED TO BUY AFTER PULLBACK: Canaccord Genuity analyst Michael Graham upgraded Square (SQ) to Buy from Hold and raised his price target for the shares to $90 from $60. The recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company," Graham said. He believes the departure of CFO Sarah Friar is more about going to a promising company as CEO rather than walking away from a risk. PIVOTAL UPGRADES SNAP TO BUY: Pivotal Research analyst Brian Wieser upgraded Snap (SNAP) to Buy from Hold while lowering his price target for the shares to $8 from $9. The analyst said that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser added. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. JPMORGAN DOWNGRADES ESTEE LAUDER TO NEUTRAL: JPMorgan analyst Andrea Teixeira downgraded Estee Lauder (EL) to Neutral and lowered her price target for the shares to $138 from $154. There may be a deceleration in the travel retail channel ahead now that Chinese customs agents are implementing tighter controls at the border, according to local source, Teixeira noted. Further, she believes the de-rating in luxury peers related to the group's "outsized exposure" to Chinese consumers will likely put a cap on Estee Lauder's valuation as well. The analyst also sees less opportunity for earnings beats on margins in the near term given tariff costs.

MSFT

Microsoft

$108.88

2.97 (2.80%)

NFLX

Netflix

$339.65

18.37 (5.72%)

SQ

Square

$73.78

4.66 (6.74%)

SNAP

Snap

$7.25

0.43 (6.31%)

EL

Estee Lauder

$127.35

-0.83 (-0.65%)

  • 16

    Oct

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Mar

MSFT Microsoft
$108.88

2.97 (2.80%)

10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Macquarie upgrades Microsoft to Outperform after pullback to 'correct' mistake
As previously reported, Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral, taking advantage of the market pullback to "correct" her rating on "a name [she has sorely missed." The company has been differentiating Azure in several critical ways that she did not fully appreciate, such as being both enterprise-friendly and aggressive in layering in unique and incremental services such as Artificial Intelligence, Azure Stack, Azure Sphere, and a broad focus on edge computing, Hindlian tells investors. Additionally, Microsoft continues to drive the business into higher-growth arenas, like public cloud and what she expects to be an emerging successful gaming services platform. While many are worrying that the company's robust earnings trend will not persist as comps get tougher, Hindlian sees ample revenue drivers and raised her price target on Microsoft shares to $121 from $106.
10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Microsoft upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral and raised its price target to $121 saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work.
10/12/18
10/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Outperform from Neutral at Macquarie with analyst Sarah Hindlian saying she is taking advantage of the pullback in shares. 2. Netflix (NFLX) upgraded to Buy from Neutral at Citi with analyst Mark May saying the valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy. 3. Square (SQ) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying the recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company." 4. Snap (SNAP) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser saying despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." 5. Costco (COST) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/08/18
BARD
10/08/18
NO CHANGE
BARD
Outperform
Microsoft Project xCloud mostly positive for game publishers, says Baird
After Microsoft (MSFT) announced details of its game-streaming initiative, Project xCloud, Baird analyst Colin Sebastian said he does not expect beta user trials until 2019, with a full launch likely 1-2 years later. The analyst, who sees the news as mostly positive for game publishers Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO), believes that streaming represents an opportunity to convert a portion of the remaining casual gamer market by providing console-quality full streaming games with the cross-platform social features of current consoles. Baird has Outperform ratings on all three game publishers mentioned.
NFLX Netflix
$339.65

18.37 (5.72%)

10/12/18
WEDB
10/12/18
NO CHANGE
Target $125
WEDB
Underperform
Netflix's valuation 'unwarranted,' says Wedbush
Wedbush analyst Michael Pachter reiterated an Underperform rating and $125 price target on Netflix ahead of the company's quarterly results, telling investors in a research note that he believes Netflix's valuation is unwarranted and that consistently negative free cash flow makes discounted cash flow valuation "impossible." Pachter says he expects content spending to trigger "substantial" cash burn for many years, and believes international profits may remain "elusive" due to competition for content and subscribers, with future price increases potentially causing a deceleration in subscriber growth.
10/12/18
MKMP
10/12/18
NO CHANGE
Target $395
MKMP
Buy
Netflix set-up attractive ahead of earnings, says MKM Partners
MKM Partners analyst Rob Sanderson kept his Buy rating and $395 price target on Netflix ahead of its earnings next week, saying that after a "meaningful" pullback in its price from the broader market volatility, the stock looks "attractive again". The analyst cites the company's "solid looking performance from the content slate", along with its new content coming and conservative looking expectations relative to its historic seasonality. Sanderson anticipates that Netflix will have many years of market cap appreciation ahead and views its fundamentals "among the best of the mega-caps".
10/12/18
SBSH
10/12/18
UPGRADE
Target $375
SBSH
Buy
Netflix upgraded to Buy from Neutral at Citi
Citi analyst Mark May upgraded Netflix to Buy from Neutral with an unchanged price target of $375. The streaming service closed yesterday down $4.79 to $321.10. The valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy, May tells investors in a research note. Netflix has a highly recurring subscription-based revenue business that delivers "significant value" to consumers, and its management team has a strong track record of execution, the analyst contends. Further, he believes the company's fundamentals remain strong and that is has opportunity to continue growing international subscribers.
SQ Square
$73.78

4.66 (6.74%)

10/11/18
WBLR
10/11/18
NO CHANGE
WBLR
Outperform
Sarah Friar 'major loss,' Square shares still expensive, says William Blair
William Blair analyst Robert Napoli views the departure of Sarah Friar as a "major loss" for Square. Friar was critical to the success of the company, its strategic direction, and the management of growth/investment versus margin expansion, Napoli tells investors in a research note. And while stock has pulled back 24% from its recent highs, it remains expensive at 25 times 2018 and 19 times 2019 enterprise value to revenue, Napoli contends. He keeps a Market Perform rating on Square, which is trading down 6%, or $4.85, to $72.60 in the premarket.
10/12/18
NOMU
10/12/18
NO CHANGE
Target $125
NOMU
Buy
Square selloff yesterday not warranted by CFO exit, says Nomura Instinet
Departing CFO Sarah Friar is important, but certainly not important enough to merit yesterday's selloff in shares of Square, Nomura Instinet analyst Dan Dolev tells investors in a research note titled "Focus on Results Not the CFO." He believes Friar's departure is "unlikely to disrupt the innovation engine behind" the company. The analyst keeps a Buy rating on Square with a $125 price target.
10/12/18
ADAM
10/12/18
UPGRADE
Target $90
ADAM
Buy
Square upgraded to Buy from Hold at Canaccord
Canaccord Genuity analyst Michael Graham upgraded Square to Buy from Hold and raised his price target for the shares to $90 from $60. The stock closed yesterday down 11%, or $8.42, to $69.03. The recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company," Graham tells investors in a research note. He believes the departure of CFO Sarah Friar is more about going to a promising company as CEO rather than walking away from a risk. Further, Graham sees "plenty of opportunity" for Graham to grow its core business.
SNAP Snap
$7.25

0.43 (6.31%)

10/11/18
10/11/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN UPGRADES LUMENTUM AFTER SELLOFF: JPMorgan analyst Samik Chatterjee upgraded Lumentum (LITE) to Overweight from Neutral with an unchanged price target of $80. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee said. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook. GOLDMAN CUTS HUNTINGTON TO SELL: Goldman Sachs analyst Noah Poponak downgraded Huntington Ingalls Industries (HII) to Sell from Neutral and lowered his price target for the shares to $208 from $220. Poponak said Huntington is now the most expensive stock in his Defense coverage on economic, price-to-earnings and free cash flow yield. The analyst believes the stock could underperform Defense peers in the medium-term given the valuation. JEFFRIES STARTS HERBALIFE WITH A BUY: Jefferies analyst Akshay Jagdale started Herbalife Nutrition (HLF) with a Buy rating and $65 price target. After a period of "muted growth," Herbalife's sales looked poised to accelerate to a more normalized range of 5%-9%, Jagdale believes. He thinks the company should be able to grow at least in line with its total addressable market growth rate of 6%. This, coupled with margin expansion and accretive free cash flow usage, should drive "significant" earnings upside and support a "growth company valuation," Jagdale said. JPMORGAN RAISES PRICE TARGET ON NY TIMES: JPMorgan analyst Alexia Quadrani raised her price target for New York Times (NYT) to $32 and reiterated an Overweight rating on the shares ahead of the company's Q3 results. The analyst said that while quarterly subscriber growth may continue to be volatile, the company's longer-term trends are positive. She expects New York Times' growth to "remain at elevated levels for the foreseeable future." SNAP PRICE TARGET CUT AT GOLDMAN SACHS: Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he said.
10/12/18
PIVT
10/12/18
UPGRADE
Target $8
PIVT
Buy
Snap upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Snap to Buy from Hold while lowering his price target for the shares to $8 from $9. The stock closed yesterday up 22c to $6.81. The analyst says that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser tells investors in a research note. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. Wieser views Snap's risk/reward as favorable following the recent selloff.
10/11/18
GSCO
10/11/18
NO CHANGE
Target $11
GSCO
Buy
Snap price target lowered to $11 from $17 at Goldman Sachs
Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he contends.
EL Estee Lauder
$127.35

-0.83 (-0.65%)

10/12/18
JPMS
10/12/18
DOWNGRADE
Target $138
JPMS
Neutral
Estee Lauder downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Andrea Teixeira downgraded Estee Lauder to Neutral and lowered her price target for the shares to $138 from $154. There may be a deceleration in the travel retail channel ahead now that Chinese customs agents are implementing tighter controls at the border, according to local source, Teixeira tells investors in a research note. Further, she believes the de-rating in luxury peers related to the group's "outsized exposure" to Chinese consumers will likely put a cap on Estee Lauder's valuation as well. The analyst also sees less opportunity for earnings beats on margins in the near term given tariff costs.
09/20/18
ATLE
09/20/18
INITIATION
Target $162
ATLE
Overweight
Estee Lauder initiated with an Overweight at Atlantic Equities
Atlantic Equities analyst Edward Lewis initiated Estee Lauder with an Overweight rating and $162 price target, stating that it offers "unique exposure" to the growing appetite of the emerging Asian millennial consumer for prestige beauty products. He sees Estee being able to deliver double digit EPS growth to support an ongoing premium valuation, Lewis tells investors.
08/28/18
08/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RH (RH) upgraded to Accumulate from Hold at Gordon Haskett. 2. Estee Lauder (EL) and Coty (COTY) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. First Business Financial (FBIZ) upgraded to Buy from Neutral at DA Davidson with analyst Kevin Reevey saying the current trading level on the stock presents an attractive entry point after its 10% month-to-date decline and a 19% retreat from its 52-week highs. 4. Regency Centers (REG) upgraded to Buy from Hold at Deutsche Bank with analyst Derek Johnston saying "clear signs" of a retail recovery has fueled the rally in strip real estate investment trusts in recent weeks. 5. Affimed N.V. (AFMD) upgraded to Buy from Hold at Jefferies with analyst Maury Raycroft saying its collaboration with Roche Group's (RHHBY) Genentech to develop and commercialize novel NK cell engagers indicate the intrinsic value in Affimed's platform and approach. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/18
08/28/18
UPGRADE
Target $14.5

Overweight
Morgan Stanley upgrades Coty, moves to Overweight for first time
As previously reported, Morgan Stanley analyst Dara Mohsenian upgraded Coty (COTY) to Overweight from Equal Weight, pointing out that this is the first time the firm has had an Overweight rating on the stock since the company's 2013 IPO. Following four sell-side downgrades in the last two weeks and the stock's 40% year-to-date decline, Mohsenian now sees the risk/reward as "compelling," he tells investors. The analyst sees improving visibility that Coty can return to steady topline growth and sees upside to adjusted consensus EBIT in FY19 and FY20, while also believing that JAB may increase its stake post the two-year lock-up restriction. Mohsenian, however, trimmed his price target on Coty shares to $14.50 from $17.00. He also upgraded beauty industry peer Estee Lauder (EL) to Overweight from Equal Weight this morning.

TODAY'S FREE FLY STORIES

01:55
02/20/19
02/20
01:55
02/20/19
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

LUV

Southwest

$57.66

0.02 (0.03%)

21:49
02/19/19
02/19
21:49
02/19/19
21:49
Downgrade
Southwest rating change at Goldman Sachs »

Southwest downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

RARE

Ultragenyx

$56.80

0.14 (0.25%)

21:17
02/19/19
02/19
21:17
02/19/19
21:17
Recommendations
Ultragenyx analyst commentary at Piper Jaffray »

Piper Jaffray positive on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

21:05
02/19/19
02/19
21:05
02/19/19
21:05
General news
Japan's exports fell 8.4% in January »

Japan's exports fell…

PANW

Palo Alto Networks

$230.19

3.46 (1.53%)

20:49
02/19/19
02/19
20:49
02/19/19
20:49
Downgrade
Palo Alto Networks rating change at Gabelli »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 25

    Feb

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

AROC

Archrock

$10.06

0.365 (3.76%)

20:33
02/19/19
02/19
20:33
02/19/19
20:33
Earnings
Archrock sees FY19 net income $73M-$103M vs. $29.2M in FY18 »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CTL

CenturyLink

$14.10

0.37 (2.69%)

20:32
02/19/19
02/19
20:32
02/19/19
20:32
Downgrade
CenturyLink rating change at RBC Capital »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

TTD

Trade Desk

$161.76

3.69 (2.33%)

20:31
02/19/19
02/19
20:31
02/19/19
20:31
Downgrade
Trade Desk rating change at Stifel »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

CVS

CVS Health

$69.92

0.39 (0.56%)

, SO

Southern Company

$48.91

0.35 (0.72%)

20:25
02/19/19
02/19
20:25
02/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CVS

CVS Health

$69.92

0.39 (0.56%)

SO

Southern Company

$48.91

0.35 (0.72%)

ADI

Analog Devices

$104.21

-1.49 (-1.41%)

HSIC

Henry Schein

$63.11

0.73 (1.17%)

OC

Owens Corning

$55.38

0.73 (1.34%)

WIX

Wix.com

$125.70

4.31 (3.55%)

WWW

Wolverine World Wide

$39.50

-0.04 (-0.10%)

CNDT

Conduent

$14.52

0.93 (6.84%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 09

    Apr

  • 28

    May

AROC

Archrock

$10.06

0.365 (3.76%)

20:21
02/19/19
02/19
20:21
02/19/19
20:21
Earnings
Archrock reports Q4 EPS 10c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AI

Arlington Asset Investment

$8.70

-0.14 (-1.58%)

20:09
02/19/19
02/19
20:09
02/19/19
20:09
Syndicate
Arlington Asset Investment 6M share Spot Secondary priced at $8.33 »

Arlington Asset announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GLD

SPDR Gold Shares

$126.70

1.89 (1.51%)

19:46
02/19/19
02/19
19:46
02/19/19
19:46
Hot Stocks
SPDR Gold Shares holdings fall to 792.45MT from 793.03MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

18:25
02/19/19
02/19
18:25
02/19/19
18:25
Conference/Events
CLSA technology analyst to hold an analyst/industry conference call »

Technology Sales…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.